Accès ouvert
2026
article
OpenAlex
Şahin Bedir, G. Sen, Hamza Abbasov, Murad Guliyev et autres
Background: We assessed the prognostic value of the pan-immune–inflammation value (PIV), systemic immune–inflammation index (SII), lung immune prognostic index (LIPI), and c-reactive protein–albumin–lymphocyte (CALLY) index in advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitor (ICI)-based therapy. Methods: This …
tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Mine Önenerk, Ayşe Hanım Namal, Ahu Senem Demiröz, Zehra Şahin et autres
Objective: Melanoma has a poor prognosis in advanced stages. The study aimed to investigate the immunohistochemical expression of Cripto-1 (CR-1) and its relationship with clinicopathological parameters in cutaneous melanoma cases. Methods: Cutaneous melanoma cases diagnosed at Cerrahpaşa Medical Faculty between January 2016 …
tr, gb
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Murat Günaltılı, Murad Guliyev, Zeliha Birsin, Emir Çerme et autres
Obesity has been associated with inferior outcomes in early-stage breast cancer, but its clinical relevance in metastatic disease treated with CDK4/6 inhibitors remains uncertain. We retrospectively analyzed 332 patients with hormone receptor-positive/HER2-negative metastatic breast cancer who received first-line ribociclib or palbociclib plus …
tr, kh, ag
(code pays fourni par la source)
2026
article
OpenAlex
Ayşegül Gündüz, Merve İriş, Zeliha Birsin, Hande Turna et autres
OBJECTIVE: This study aimed to identify the frequency and types of peripheral nervous system involvement, associated clinical features, treatment options, and prognosis in patients receiving immune checkpoint inhibitors (ICIs) for the treatment of malignancy. METHOD: This is a retrospective cross-sectional study. We …
tr
(code pays fourni par la source)
2026
article
OpenAlex
Cansu Güneren, Lebriz Uslu, Onur Erdem Şahin, Ayşe Mine Önenerk Men et autres
tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Emir Çerme, Şebnem Batur, Cansu Yol, Eray Öntaş et autres
Background/Objectives: Immune checkpoint inhibitors (ICIs) improve outcomes in metastatic non-squamous non-small cell lung cancer (NSCLC), yet predictive biomarkers remain limited. This study investigated whether CD34-stained microvessel density (MVD) is associated with ICI efficacy. Methods: Patients with metastatic non-squamous NSCLC and tumor specimen …
tr, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Zeliha Birsin, Emir Çerme, Ceyda Sönmez Wetherilt, Hande Turna
Intratumoral heterogeneity poses a significant challenge in the management of metastatic hormone receptor-positive (HR + ), human epidermal growth factor receptor 2 (HER2)-negative (HER2 -) breast cancer (BC), as it may contribute to treatment resistance and disease progression.Two cases of de novo …
tr
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Kübra Canaslan, Emre Eken, Mehmet Bilici, Fahriye Merve Balcıoğlu et autres
BACKGROUND/OBJECTIVES: Genomic profiling guides treatment in metastatic non-small-cell lung cancer (mNSCLC), yet country-level data from Türkiye remain limited. METHODS: We retrospectively analyzed consecutive patients with mNSCLC diagnosed between January 2018 and March 2025 across tertiary centers in all seven regions. Variables included …
tr
(code pays fourni par la source)
2025
article
OpenAlex
Hande Turna
PURPOSE OF REVIEW: There is a complex relationship between nonhematological malignancies and vasculitis Paraneoplastic vasculitis may present in many different forms. Cancer risk is high in patients with some types of vasculitis. Also, immune checkpoint inhibitors (ICIs) used in treatment of many …
tr
(code pays fourni par la source)
2025
article
OpenAlex
Melek Ağkoç, Hüseyin Melek, Hande Turna, Fazilet Öner Dinçbaş et autres
tr
(code pays fourni par la source)
Accès ouvert
2025
conference-paper
OpenAlex
Gaye Su Yiğit, Gülçin Özcan Ateş, Hande Turna
Accès ouvert
2025
article
OpenAlex
Ali Kaan Güren, Hilal Türkben Polat, Eyüp Çoban, Emir Çerme et autres
BACKGROUND: Fibrolamellar Hepatocellular Carcinoma (FLHCC) is a rare primary liver tumour that is distinct from conventional HCC in both histopathological and clinical features. There is no clear consensus on its treatment. OBJECTIVE: Assess the demographics, prognosis, and treatment— particularly systemic therapies—of FLHCC …
tr, gb
(code pays fourni par la source)